Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II MAP +/- denosumab in metastatic osteosarcoma
2024-518167-35-01Phase 2Authorised
- Sponsor
- Italian Association of Pediatric Hematology and Oncology
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of denosumab in osteosarcoma (OS) (2 arms), sponsored by Italian Association of Pediatric Hematology and Oncology. Primary endpoint: 3-year event-free survival. Planned start Dec 2024; status: authorised.
02
Drugs
denosumab
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on 2024-518167-35-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518167-35-01.